statement was released by the rating agency) NEW YORK, December 18 (Fitch) Fitch Ratings has affirmed Banco de Costa Rica's ( BCR ) Issuer Default Rating (IDR) at 'BB+' and short term IDR at 'B'. Fitch also affirms BCRs Viability Rating (VR) at
CR Bard reported robust third-quarter results that were generally consistent with our projections. While we have not made any significant
We have long appreciated CR Bard 's narrow economic moat and have recently taken another look at the firm's product portfolio and general approach to navigating
in constant currency, propelled by urology and women's products. Moreover, the electrophysiology business purchased from CR Bard provided a boost by rounding out Boston's portfolio with complementary products. Boston held gross margin steady at 70
CR Bard reported first-quarter results that slightly exceeded our expectations, thanks to acquisitions made last year as well as royalty
CR Bard released solid fourth-quarter performance that generally matched our expectations, and we are leaving our fair value estimate
see China as a strategic priority and invested heavily to put down roots there. On the other hand, Edwards EW and C . R . Bard BCR have invested far less extensively in China and do not seem to view penetration of this market as a corporate priority
CR Bard posted strong third-quarter results that slightly exceeded our expectations. We plan to modestly raise our fair value estimate
increased its litigation reserve to $216 million to account for the increase, but based on recent settlements of similar cases against competitors such as C . R . Bard , it wouldn't be surprising to see the final expense exceed that amount.
(Reuters) - Medical device company C . R . Bard Inc said it would buy Rochester Medical Inc, which makes products for urinary retention and incontinence, for about $262 million to boost its presence in...